Trial Title:
Cabozantinib in Combination With Atezolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer
NCT ID:
NCT06006013
Condition:
Locally Advanced Adrenal Cortex Carcinoma
Adrenal Cortical Carcinoma
Stage III Adrenal Cortex Carcinoma
Stage IV Adrenal Cortex Carcinoma AJCC v8
Unresectable Adrenal Cortex Carcinoma
Conditions: Official terms:
Carcinoma
Adrenocortical Carcinoma
Atezolizumab
Antibodies, Monoclonal
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Active, not recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Biological
Intervention name:
Atezolizumab
Description:
Given IV
Arm group label:
Treatment (cabozantinib, Atezolizumab)
Other name:
MPDL 3280A
Other name:
MPDL 328OA
Other name:
MPDL-3280A
Other name:
MPDL3280A
Other name:
MPDL328OA
Other name:
RG7446
Other name:
RO5541267
Other name:
Tecentriq
Intervention type:
Procedure
Intervention name:
Biospecimen Collection
Description:
Undergo collection of blood samples
Arm group label:
Treatment (cabozantinib, Atezolizumab)
Other name:
Biological Sample Collection
Other name:
Biospecimen Collected
Other name:
Specimen Collection
Intervention type:
Drug
Intervention name:
Cabozantinib S-malate
Description:
Given PO
Arm group label:
Treatment (cabozantinib, Atezolizumab)
Other name:
Cabometyx
Other name:
Cometriq
Intervention type:
Procedure
Intervention name:
Computed Tomography
Description:
Undergo CT
Arm group label:
Treatment (cabozantinib, Atezolizumab)
Other name:
CAT
Other name:
CAT Scan
Other name:
Computed Axial Tomography
Other name:
Computerized Axial Tomography
Other name:
Computerized axial tomography (procedure)
Other name:
Computerized Tomography
Other name:
CT
Other name:
CT Scan
Other name:
tomography
Intervention type:
Procedure
Intervention name:
Magnetic Resonance Imaging
Description:
Undergo MRI
Arm group label:
Treatment (cabozantinib, Atezolizumab)
Other name:
Magnetic Resonance
Other name:
Magnetic resonance imaging (procedure)
Other name:
Magnetic Resonance Imaging Scan
Other name:
Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance
Other name:
MR
Other name:
MR Imaging
Other name:
MRI
Other name:
MRI Scan
Other name:
Nuclear Magnetic Resonance Imaging
Summary:
This phase II trial tests how well cabozantinib in combination with atezolizumab works in
treating patients with adrenocortical cancer that has spread to nearby tissue or lymph
nodes (locally advanced), that has spread from where it first started (primary site) to
other places in the body (metastatic), or that cannot be removed by surgery
(unresectable). Cabozantinib inhibits receptor tyrosine kinases, which are receptors
commonly over-expressed by tumor cells. This may result in an inhibition of both tumor
growth and blood vessel formation, eventually leading to a decrease in tumor size or
extent in the body. Immunotherapy with monoclonal antibodies, such as atezolizumab, may
help the body's immune system attack the cancer and may interfere with the ability of
tumor cells to grow and spread. Adding cabozantinib to atezolizumab may be more effective
at treating patients with adrenal cortical cancer than giving these drugs alone.
Detailed description:
PRIMARY OBJECTIVE:
I. To evaluate the anti-tumor activity of the combination of cabozantinib S-malate
(cabozantinib) and Atezolizumab by assessing the overall response rate (ORR) as measured
by Response Evaluation Criteria in Solid Tumors (RECIST 1.1.).
SECONDARY OBJECTIVE:
I. To evaluate the efficacy of the combination of cabozantinib and Atezolizumab as
measured by progression free survival and overall survival assessed up to 2 years, safety
and tolerability of the combination.
TERTIARY/EXPLORATORY OBJECTIVE:
I. To assess tissue-based assays in archival tissue and correlative changes in peripheral
T-cell subsets, myeloid derived suppressor cells (MDSC), blood inflammatory markers and
cytokines.
OUTLINE:
Patients receive cabozantinib orally (PO) once daily (QD) on days 1-21 of each cycle and
Atezolizumab intravenously (IV) over 30-60 minutes on day 1 of each cycle. Cycles repeat
every 21 days in the absence of disease progression or unacceptable toxicity. Patients
also undergo computed tomography (CT) and/or magnetic resonance imaging (MRI) at
screening and then every 12 weeks on study and undergo collection of blood samples at
screening, on study, and at end of treatment. Patients without archival tissue also
undergo biopsy at screening.
After completion of study treatment, patients are followed for 28 days and then up to 2
years
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Male or female
- Age >= 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 ,Karnofsky >= 50%.
- Metastatic disease or unresectable locally advanced disease.
- Histologically documented adrenal cortical carcinoma.
- Untreated or having received any number of lines of prior therapy.
- Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version
(v)1.1
- Life expectancy >= 12 weeks
- Tumor tissue samples must be available for submission prior to initiation of study
treatment. If not, agree to undergo biopsy.
- Recovery to baseline or =< grade 1 Common Terminology Criteria for Adverse Events
(CTCAE) version 5 from toxicities related to any prior treatments, unless adverse
event (AE)(s) are clinically nonsignificant and/or stable on supportive therapy.
- Absolute neutrophil count (ANC) >= 1500/uL without granulocyte colony-stimulating
factor support within 28 days before first dose of study treatment.
- Lymphocyte count 0.5 x 10^9/L (500/mL) within 28 days before first dose of study
treatment.
- White blood cell count >= 2500/uL within 28 days before first dose of study
treatment.
- Platelets >= 100,000/uL without transfusion within 28 days before first dose of
study treatment.
- Hemoglobin >= 9 g/dL (>= 90 g/L). Patients may be transfused to meet this criterion
within 28 days before first dose of study treatment.
- Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline
phosphatase (ALP) =< 3 x upper limit of normal (ULN). ALP =< 5 x ULN with documented
bone metastases within 28 days before first dose of study treatment.
- Total bilirubin =< 1.5 x ULN for subjects with Gilbert's disease =< 3 x ULN within
28 days before first dose of study treatment.
- Serum albumin >= 2.8 g/dl within 28 days before first dose of study treatment.
- Prothrombin time (PT) / international normalized ratio (INR) or partial
thromboplastin time (PTT) test < 1.3 x the laboratory ULN within 28 days before
first dose of study treatment.
- Serum creatinine =< 1.5 x ULN or calculated creatinine clearance >= 40mL/min (>=
0.675mL/sec) using the Cockcroft-Gault equation within 28 days before first dose of
study treatment.
- Urine protein/creatinine ratio (UPCR) =< 1 mg/mg (=< 113.2 mg/mmol), or 24-h urine
protein =< 1 g within 28 days before first dose of study treatment.
- Negative human immunodeficiency virus (HIV) test at screening, with the following
exception: patients with a positive HIV test at screening are eligible provided they
are stable on anti-retroviral therapy, have a CD4 count >= 200/uL, and have an
undetectable viral load.
- Negative hepatitis B surface antigen (HBsAg) test at screening.
- Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV
antibody test followed by a negative hepatitis C virus (HCV) ribonucleic acid (RNA)
test at screening.
- The hepatitis C virus (HCV) ribonucleic acid (RNA) test must be performed for
patients who have a positive HCV antibody test
- The effects of study drugs on the developing human fetus are unknown. For this
reason, female of child-bearing potential (FCBP) must have a negative serum or urine
pregnancy test prior to starting therapy
- Female of child-bearing potential (FCBP) and men treated or enrolled on this
protocol must agree to use adequate contraception with a failure rate < 1% prior to
study entry, for the duration of study participation, and 5 months after completion
of study drug administration.
- Examples of contraceptive methods with a failure rate of < 1% per year include
bilateral tubal ligation, male sterilization, hormonal contraceptives that
inhibit ovulation, hormone-releasing intrauterine devices, and copper
intrauterine devices
- The reliability of sexual abstinence should be evaluated in relation to the
duration of the clinical trial and the preferred and usual lifestyle of the
patient. Periodic abstinence e.g., calendar, ovulation, symptothermal, or
postovulation methods and withdrawal are not adequate methods of contraception
- Should a woman become pregnant or suspect she is pregnant while she or her
partner is participating in this study, she should inform her treating
physician immediately
- Female subjects of childbearing potential must not be pregnant at screening. Female
subjects are considered to be of childbearing potential unless one of the following
criteria is met: documented permanent sterilization (hysterectomy, bilateral
salpingectomy, or bilateral oophorectomy) or documented postmenopausal status
(defined as 12 months of amenorrhea in a woman > 45 years-of-age in the absence of
other biological or physiological causes. In addition, females < 55 years-of-age
must have a serum follicle stimulating [FSH] level > 40 mIU/mL to confirm
menopause). Note: Documentation may include review of medical records, medical
examinations, or medical history interview by study site
- Willingness and ability of the subject to comply with scheduled visits, drug
administration plan, protocol-specified laboratory tests, other study procedures,
and study restrictions
- Evidence of a personally signed informed consent indicating that the subject is
aware of the neoplastic nature of the disease and has been informed of the
procedures to be followed, the experimental nature of the therapy, alternatives,
potential risks and discomforts, potential benefits, and other pertinent aspects of
study participation
Exclusion Criteria:
- Receipt of any type of small molecule kinase inhibitor including investigational
kinase inhibitor within 2 weeks before first dose of study treatment
- Prior treatment with CD137 agonists or immune checkpoint blockade therapies,
including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies
- Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy
(including immunostimulatory agents or investigational agents) within 4 weeks or 5
half-lives of the drug (whichever is longer) before first dose of study treatment
- Radiation therapy for bone metastasis within 2 weeks or any other radiation therapy
within 4 weeks before first dose of study treatment. Systemic treatment with
radionuclides within 6 weeks before first dose of study treatment. Subjects with
clinically relevant ongoing complications from prior radiation therapy are not
eligible
- Known brain metastases or cranial epidural disease unless adequately treated with
radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks
prior to first dose of study treatment after radiotherapy or at least 4 weeks prior
to first dose of study treatment after major surgery (e.g., removal or biopsy of
brain metastasis). Subjects with known brain metastases or cranial epidural disease
should also have no history of intracranial hemorrhage or spinal hemorrhage.
Subjects must have complete wound healing from major surgery or minor surgery before
first dose of study treatment. Eligible subjects must be neurologically asymptomatic
and without corticosteroid treatment at the time of first dose of study treatment.
If subject is receiving anti-convulsant therapy, the dose is considered stable
- Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin
inhibitors (e.g., dabigatran), direct factor Xa inhibitor betrixaban, or platelet
inhibitors (e.g., clopidogrel). Allowed anticoagulants are the following:
- Prophylactic use of low-dose aspirin for cardio-protection (per local
applicable guidelines) and low-dose low molecular weight heparins (LMWH)
- Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors
rivaroxaban, edoxaban, or apixaban in subjects without known brain metastases
who are on a stable dose of the anticoagulant for at least 1 week before first
dose of study treatment without clinically significant hemorrhagic
complications from the anticoagulation regimen or the tumor
- Administration of a live, attenuated vaccine within 30 days before first dose of
study treatment or anticipation of need for such a vaccine during atezolizumab
treatment or within 5 months after the final dose of atezolizumab
- Concomitant mitotane use
- Mitotane must have been discontinued 28 days prior to first dose of study
treatment, with mitotane serum level < 2 mg/L if mitotane administered within
last 6 months
- The subject has uncontrolled, significant intercurrent or recent illness including,
but not limited to, the following conditions:
- Cardiovascular disorders:
- Congestive heart failure New York Heart Association class 3 or 4, unstable
angina pectoris, serious cardiac arrhythmias
- Uncontrolled hypertension defined as sustained blood pressure (BP) > 140
mm Hg systolic or > 90 mm Hg diastolic despite optimal antihypertensive
treatment
- Stroke, including transient ischemic attack (TIA), myocardial infarction
(MI), or other ischemic event, or thromboembolic event (e.g., deep venous
thrombosis, pulmonary embolism) within 6 months before first dose of study
treatment
- Subjects with a diagnosis of incidental, subsegmental pulmonary
embolism (PE) or deep vein thrombosis (DVT) within 6 months are
allowed if stable, asymptomatic, and treated with a stable dose of
permitted anticoagulation (see exclusion criterion #6) for at least 1
week before first dose of study treatment
- Gastrointestinal (GI) disorders including those associated with a high risk of
perforation or fistula formation:
- The subject has evidence of tumor invading the GI tract, active peptic
ulcer disease, inflammatory bowel disease (e.g., Crohn's disease),
diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis,
acute pancreatitis, acute obstruction of the pancreatic duct or common
bile duct, or gastric outlet obstruction
- Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal
abscess within 6 months before first dose of study treatment. Note:
Complete healing of an intra-abdominal abscess must be confirmed before
first dose of study treatment
- Uncontrolled tumor-related pain:
- Patients requiring pain medication must be on a stable regimen at study
entry
- Symptomatic lesions e.g., bone metastases or metastases causing nerve
impingement amenable to palliative radiotherapy should be treated prior to
enrollment. Patients should be recovered from the effects of radiation
(see exclusion criteria #4 for minimal required duration prior to trial
enrollment)
- Asymptomatic metastatic lesions that would likely cause functional
deficits or intractable pain with further growth (e.g., epidural
metastasis that is not currently associated with spinal cord compression)
should be considered for loco-regional therapy if appropriate prior to
enrollment
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring
recurrent drainage procedures (once monthly or more frequently)
- Patients with indwelling catheters (e.g., PleurX) are allowed
- Uncontrolled or symptomatic hypercalcemia (ionized calcium > 1.5 mmol/L,
calcium > 12 mg/dL or corrected serum calcium > ULN)
- History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g.,
bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis,
or evidence of active pneumonitis on screening chest computed tomography (CT)
scan
- History of radiation pneumonitis in the radiation field (fibrosis) is
permitted
- Clinically significant hematuria, hematemesis, or hemoptysis of > 0.5 teaspoon (2.5
ml) of red blood, or other history of significant bleeding (e.g., pulmonary
hemorrhage) within 12 weeks before first dose of study treatment
- Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease
manifestation
- Lesions invading or encasing any major blood vessels
- Other clinically significant disorders that would preclude safe study participation.
- Active or history of autoimmune disease or immune deficiency, including, but
not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic
lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease,
antiphospholipid antibody syndrome, Wegener granulomatosis, Sjogren syndrome,
Guillain-Barré syndrome, or multiple sclerosis with the following exceptions:
- Type 1 diabetes mellitus on an insulin regimen
- Hypothyroidism only requiring hormone replacement
- Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo
with dermatologic manifestations only (e.g., patients with psoriatic
arthritis are excluded) are eligible for the study provided all of
following conditions are met:
- Rash must cover < 10% of body surface area
- Disease is well controlled at baseline and requires only low-potency
topical corticosteroids
- No occurrence of acute exacerbations of the underlying condition
requiring psoralen plus ultraviolet A radiation, methotrexate,
retinoids, biologic agents, oral calcineurin inhibitors, or
high-potency or oral corticosteroids within the previous 12 months
- Treatment with systemic immunosuppressive medication (including, but not
limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate,
thalidomide, and anti-tumor necrosis factor [TNF]-alpha agents) within 2 weeks
prior to initiation of study treatment, or anticipation of need for systemic
immunosuppressive medication during study treatment, with the following
exceptions:
- Patients who received acute, low-dose systemic immunosuppressant
medication or a one-time pulse dose of systemic immunosuppressant
medication (e.g., 48 hours of corticosteroids for a contrast allergy) are
eligible for the study after principal investigator confirmation has been
obtained
- Patients who received mineralocorticoids (e.g., fludrocortisone),
corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma
or mitotane-associated adrenal insufficiency, or low-dose corticosteroids
for orthostatic hypotension or other causes of adrenal insufficiency are
eligible for the study
- Inhaled, intranasal, intra-articular, or topical steroids are permitted
- Active infection requiring systemic treatment. Acute or chronic hepatitis B or
C infection, known human immunodeficiency virus (HIV) or acquired
immunodeficiency syndrome (AIDS)-related illness, or known positive test for
tuberculosis infection where there is clinical or radiographic evidence of
active mycobacterial infection
- Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to
initiation of study treatment
- Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract
infection or chronic obstructive pulmonary disease exacerbation) are eligible
for the study
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on
screening chest CT scan
- History of radiation pneumonitis in the radiation field (fibrosis) is
permitted
- Serious non-healing wound/ulcer/bone fracture
- Malabsorption syndrome
- Uncompensated/symptomatic hypothyroidism
- Moderate to severe hepatic impairment (Child-Pugh B or C)
- Requirement for hemodialysis or peritoneal dialysis
- History of solid organ or allogenic stem cell transplant
- Known history of COVID-19 unless the subject has clinically recovered from the
disease at least 30 days prior to first dose of study treatment
- Severe infection within 4 weeks prior to initiation of study treatment,
including, but not limited to, hospitalization for complications of infection,
bacteremia, or severe pneumonia, or any active infection that could impact
patient safety
- Major surgery (e.g., laparoscopic nephrectomy, GI surgery, removal or biopsy of
brain metastasis) within 2 weeks before first dose of study treatment. Minor
surgeries within 10 days before first dose of study treatment. Subjects must have
complete wound healing from major surgery or minor surgery before first dose of
study treatment. Subjects with clinically relevant ongoing complications from prior
surgery are not eligible
- Corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms per
electrocardiogram (ECG) within 14 days before first dose of study treatment.
Furthermore, subjects with a history of additional risk factors for torsades de
pointes (e.g., long QT syndrome) are also excluded. Note: If a single ECG shows a
QTcF with an absolute value > 500 ms, two additional ECGs at intervals of
approximately 3 min must be performed within 30 min after the initial ECG, and the
average of these three consecutive results for QTcF will be used to determine
eligibility
- Pregnant or lactating females
- Inability to swallow tablets or unwillingness or inability to receive IV
administration
- Previously identified allergy or hypersensitivity to components of the study
treatment formulations or history of severe infusion-related reactions to monoclonal
antibodies. Subjects with rare hereditary problems of galactose intolerance, the
Lapp lactase deficiency or glucose-galactose malabsorption are also excluded
- Any other active malignancy at time of first dose of study treatment or diagnosis of
another malignancy within 3 years prior to first dose of study treatment that
requires active treatment, except for locally curable cancers that have been
apparently cured, such as basal or squamous cell skin cancer, superficial bladder
cancer, or carcinoma in situ of the prostate, cervix, or breast
- Current treatment with anti-viral therapy for hepatitis B virus (HBV).
- History of leptomeningeal disease
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Emory University Hospital Midtown
Address:
City:
Atlanta
Zip:
30308
Country:
United States
Facility:
Name:
Emory University Hospital/Winship Cancer Institute
Address:
City:
Atlanta
Zip:
30322
Country:
United States
Start date:
March 5, 2024
Completion date:
December 16, 2025
Lead sponsor:
Agency:
Emory University
Agency class:
Other
Collaborator:
Agency:
National Cancer Institute (NCI)
Agency class:
NIH
Source:
Emory University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06006013
